Akito Shindo

Akito Shindo

Auto-generated profile, based on publicly available information

Akito Shindo

Department of Cardiovascular Medicine (H.Y., H.A., Q.L., M.U., H.K., R.M., A.S., S.O., T.U., A.S.-K., K.U., N.T.), Graduate School of Medicine, the University of Tokyo, Japan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2024 in JACC: Basic To Translational Science
Verified
Journal Article
Open access
SIShunsuke Inoue
Shunsuke Inoue
TKToshiyuki Ko
Toshiyuki Ko
ASAkito Shindo
Akito Shindo
SNSeitaro Nomura
Seitaro Nomura
TYTakanobu Yamada
Takanobu Yamada
IKIssei Komuro
Issei Komuro
Although clonal hematopoiesis of indeterminate potential (CHIP) is an adverse prognostic factor for atherosclerotic disease, its impact on nonischemic dilated cardiomyopathy (DCM) is elusive. The authors performed whole-exome sequencing and deep target sequencing among 198 patients with DCM and detected germline mutations in cardiomyopathy-related genes and somatic mutations in CHIP driver genes. Twenty-five CHIP driver mutations were detected in 22 patients with DCM. Ninety-two patients had cardiomyopathy-related pathogenic mutations. Multivariable analysis revealed that CHIP was an independent risk factor of left ventricular reverse remodeling, irrespective of known prognostic factors. CHIP exacerbated cardiac systolic dysfunction and fibrosis in a DCM murine model. The identification of germline and somatic mutations in patients with DCM predicts clinical prognosis.

1 March 2025 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
HYHiroki Yagi
Hiroki Yagi
HAHiroshi Akazawa
Hiroshi Akazawa
QLQing Liu
Qing Liu
KYKimiko Yamamoto
Kimiko Yamamoto
KNKan Nawata
Kan Nawata
IKIssei Komuro
Issei Komuro
BACKGROUND: Marfan syndrome (MFS) is an inherited disorder caused by mutations in the FBN1 gene encoding fibrillin-1, a matrix component of extracellular microfibrils. The main cause of morbidity and mortality in MFS is thoracic aortic aneurysm and dissection, but the underlying mechanisms remain undetermined. METHODS: To elucidate the role of endothelial XOR (xanthine oxidoreductase)–derived reactive oxygen species in aortic aneurysm progression, we inhibited in vivo function of XOR either by endothelial cell (EC)–specific disruption of the Xdh gene or by systemic administration of an XOR inhibitor febuxostat in MFS mice harboring the Fbn1 missense mutation p.(Cys1041Gly). We assessed the aberrant activation of mechanosensitive signaling in the ascending aorta of Fbn1 C1041G/+ mice. Further analysis of human aortic ECs investigated the mechanisms by which mechanical stress upregulates XOR expression. RESULTS: We found a significant increase in reactive oxygen species generation in the ascending aorta of patients with MFS and Fbn1 C1041G/+ mice, which was associated with a significant increase in protein expression and enzymatic activity of XOR protein in aortic ECs. Genetic disruption of Xdh in ECs or treatment with febuxostat significantly suppressed aortic aneurysm progression and improved perivascular infiltration of macrophages. Mechanistically, mechanosensitive signaling involving FAK (focal adhesion kinase)–p38 MAPK (p38 mitogen-activated protein kinase) and Egr-1 (early growth response-1) was aberrantly activated in the ascending aorta of Fbn1 C1041G/+ mice, and mechanical stress on human aortic ECs upregulated XOR expression through Egr-1 upregulation. Consistently, EC-specific knockout of XOR or systemic administration of febuxostat in Fbn1 C1041G/+ mice suppressed reactive oxygen species generation, FAK–p38 MAPK activation, and Egr-1 upregulation. CONCLUSIONS: Aberrant activation of mechanosensitive signaling in vascular ECs triggered endothelial XOR activation and reactive oxygen species generation, which contributes to the progression of aortic aneurysms in MFS. These findings highlight a drug repositioning approach using a uric acid–lowering drug febuxostat as a potential therapy for MFS.

1 January 2026 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
HYHiroki Yagi
Hiroki Yagi
HAHiroshi Akazawa
Hiroshi Akazawa
QLQing Liu
Qing Liu
SISayo M. Ito
Sayo M. Ito
MUMasahiko Umei
Masahiko Umei
IKIssei Komuro
Issei Komuro
BACKGROUND: Marfan syndrome is an inherited disorder caused by FBN1 gene mutations, which can lead to thoracic aortic aneurysm and dissection. Selective AT 1 (angiotensin II type 1) receptor blockade is a preventive option against Marfan syndrome aortopathy, and recent clinical studies demonstrated that the inhibitory effect of an ARB (AT 1 receptor blocker) losartan on aortic aneurysm growth is equivalent to that of β-blockers. At present, several ARBs are clinically available, and they have drug-specific differences in pharmacological properties. Especially, inverse agonism of ARBs has potential benefits for cardiovascular protection, but its impact on Marfan syndrome aortopathy remains poorly understood. METHODS: Candesartan-7H is a candesartan derivative that lacks the carboxyl group critical for inverse agonist activity and works as a neutral antagonist for the AT 1 receptor. Candesartan cilexetil (1 mg/kg per day), candesartan-7H (1 or 20 mg/kg per day), or vehicle was administered to Fbn1 C1041G/+ mice, and aortic dilatation was analyzed using echocardiography, histological staining, and in situ MMP (matrix metalloproteinase) assay. Activation of TGF-β (transforming growth factor β) signaling and mechanosensitive signaling was studied using Western blot and immunohistochemical analysis. RESULTS: Candesartan cilexetil (1 mg/kg per day) and candesartan-7H (20 mg/kg per day) lowered blood pressures equally in Fbn1 C1041G/+ mice. Progressive dilatation of the aorta in association with aortic wall thickening, degeneration of elastic fibers, deposition of collagen, MMP activation, and TGF-β signaling activation in Fbn1 C1041G/+ mice was significantly suppressed by treatment with candesartan cilexetil (1 mg/kg per day), but not by candesartan-7H, even at 20 mg/kg per day. In addition, candesartan cilexetil, but not candesartan-7H, suppressed activation of mechanosensitive signaling involving focal adhesion kinase, p38 mitogen-activated protein kinase, and early growth response-1 in the ascending aorta of Fbn1 C1041G/+ mice. CONCLUSIONS: Our findings support a crucial role of inverse agonist activity of ARB for the prevention of mechanical stress-induced AT 1 receptor activation and aortic aneurysm progression in Marfan syndrome mice.

1 March 2025 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
YSYasuyuki Shiraishi
Yasuyuki Shiraishi
NNNozomi Niimi
Nozomi Niimi
SKShun Kohsaka
Shun Kohsaka
KHKazumasa Harada
Kazumasa Harada
TKTakashi Kohno
Takashi Kohno
MTMorimasa Takayama
Morimasa Takayama
BACKGROUND: The absence of practice standards in vasoactive agent usage for acute decompensated heart failure has resulted in significant treatment variability across hospitals, potentially affecting patient outcomes. This study aimed to assess temporal trends and institutional differences in vasodilator and inotrope/vasopressor utilization among patients with acute decompensated heart failure, considering their clinical phenotypes. METHODS: Data were extracted from a government-funded multicenter registry covering the Tokyo metropolitan area, comprising consecutive patients hospitalized in intensive/cardiovascular care units with a primary diagnosis of acute decompensated heart failure between January 2013 and December 2021. Clinical phenotypes, that is, pulmonary congestion or tissue hypoperfusion, were defined through a comprehensive assessment of clinical signs and symptoms, vital signs, and laboratory findings. We assessed the frequency and temporal trends in phenotype-based drug utilization of vasoactive agents and investigated institutional characteristics associated with adopting the phenotype-based approach using generalized linear mixed-effects models, with random intercepts to account for hospital-level variability. RESULTS: Among 37 293 patients (median age, 80 years; 43.7% female), 88.6% and 21.2% had pulmonary congestion and tissue hypoperfusion status, respectively. Throughout the study period, both overall and phenotype-based vasodilator utilizations showed significant declines, with overall usage dropping from 61.4% in 2013 to 48.6% in 2021 ( P trend <0.001). Conversely, no temporal changes were observed in overall inotrope/vasopressor utilization from 24.6% in 2013 to 25.8% in 2021 or the proportion of phenotype-based utilization. Notably, there was considerable variability in phenotype-based drug utilization among hospitals, with a median ranging from 48.3% to 77.8%. In multivariable-adjusted models, a higher number of board-certified cardiologists were significantly associated with lower rates of phenotype-based vasodilator utilization and reduced inappropriate inotrope/vasopressor utilization, while tertiary care hospitals were linked to more appropriate inotrope/vasopressor utilization. CONCLUSIONS: Substantial variability existed among hospitals in phenotype-based drug utilization of vasoactive agents for patients with acute decompensated heart failure, highlighting the need for standardized treatment protocols. REGISTRATION: URL: https://www.umin.ac.jp/ctr/index.htm ; Unique identifier: UMIN000013128.

18 August 2025 in European Heart Journal Open
Verified
Journal Article
Open access
ASAkito Shindo
Akito Shindo
HAHiroshi Akazawa
Hiroshi Akazawa
TUTomomi Ueda
Tomomi Ueda
HKHiroshi Kadowaki
Hiroshi Kadowaki
JIJunichi Ishida
Junichi Ishida
IKIssei Komuro
Issei Komuro
Aims: Chronic myeloid leukemia (CML) patients are at high risk for developing cardiovascular (CV) diseases due to adverse effects of BCR-ABL tyrosine kinase inhibitors. Objectives: The purpose of this study was to compare patient characteristics and in-hospital mortality between CML patients and non-CML patients, who were hospitalized for ischemic heart disease (IHD). Methods and results: This study was based on the Japanese Registry of All Cardiac and Vascular Diseases and the Diagnosis Procedure Combination (JROAD-DPC) database. All patients who were first hospitalized for IHD and received percutaneous coronary intervention from April 2012 to March 2021 were extracted. Propensity score matching was used to reduce confounding effects related to differences in patient background. A total of 766 385 patients, in which 371 CML patients were included, were analyzed. CML patients were more likely to be male and less likely to have obesity, hypertension, and dyslipidemia. The number of modifiable CV risk factors (obesity, smoking, hypertension, dyslipidemia, and diabetes mellitus) in CML patients was smaller than in non-CML patients. There was no difference in in-hospital mortality, whether considering all cases or only acute myocardial infarction cases. This was also statistically non-significant after propensity score matching. Conclusion: CML patients were hospitalized for IHD with fewer CV risk factors than non-CML patients, and in-hospital mortality was comparable between CML and non-CML patients. These findings emphasize the need for more stringent management of modifiable CV risk factors for CML patients.

1 June 2026 in Circulation: Heart Failure
Verified
Journal Article
Closed access
TJTakahiro Jimba
Takahiro Jimba
SKShun Kohsaka
Shun Kohsaka
YSYasuyuki Shiraishi
Yasuyuki Shiraishi
MTMakoto Takei
Makoto Takei
KHKazumasa Harada
Kazumasa Harada
MTMorimasa Takayama
Morimasa Takayama
BACKGROUND: Acute decompensated heart failure (ADHF) exhibits seasonal variations, yet the short-term effects of ambient temperature, independent of seasonality, remain poorly studied. Moreover, temperature-sensitive exacerbation phenotypes are not well defined, limiting the development of effective preventive strategies. We aimed to investigate the effects of ambient temperature on ADHF admissions and clinical presentation profiles. METHODS: We included 26 874 patients with ADHF who had been registered in the Tokyo Cardiovascular Care Unit Network Database between January 2014 and December 2019. The onset date of ADHF leading to hospitalization, along with clinical characteristics such as age, left ventricular function, cause of ADHF, and hemodynamic profile, was assessed by cardiologists at each participating center. Climate data were obtained from an observatory near the admitting hospital. We used a time-stratified case-crossover design with distributed lag nonlinear models to explore the association between ambient temperature and ADHF admissions over lag days 0 to 5, with stratified analyses by the clinical presentations. RESULTS: Exposure to extremely low temperatures (−4.5 °C [first percentile]) increased the risk of ADHF (1.80, 95% CI, 1.40–2.31) when referenced to the temperature of lowest risk (29.0 °C [99th percentile]). The excess risk of lower temperature appeared immediately on the day of exposure (lag 0). This risk was larger in patients aged ≥70 years and otherwise consistent across subgroups. Notably, the temperature-risk relationship differed by hemodynamic profiles; risk for ADHF with hypertension rose at low temperatures, whereas ADHF with low blood pressure showed the opposite pattern, with risk increasing at high temperatures (odds ratio, 6.25 [95% CI, 1.07–36.6] at the 99th percentile). CONCLUSIONS: Low ambient temperature increased ADHF risk, especially in older adults, while temperature effects differed by hemodynamic phenotype. Incorporating temperature exposure into risk assessment may enable targeted prevention of climate-related decompensation. REGISTRATION: URL: https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015310 ; Unique identifier: UMIN000013128.